Table 1.

Demographic data for canine subjects and experimental treatment schedule

VariableLevel/unitAll dogsDose 1Dose 2Dose 3ControlPaPb
A. Baseline characteristics for all dogs and by dose summarized by N (%) or mean (SD)
AgeYears9.4 (1.7)9.2 (1.6)9.5 (1.8)8.6 (1.7)10.5 (2.2)0.0540.135
SexM11 (47.8)1 (33.3)9 (52.9)1 (33.3)13 (46.4)10.763
F12 (52.2)2 (66.7)8 (47.1)2 (66.7)15 (53.6)
BCS5.7 (1)5.7 (0.6)5.5 (1.1)6.3 (0.6)5.2 (1)c0.1590.385
HemoabdomenY20 (87)2 (66.7)15 (88.2)3 (100)22 (78.6)0.4870.69
N3 (13)1 (33.3)2 (11.8)0 (0)6 (21.4)
StageI2 (8.7)0 (0)2 (11.8)0 (0)5 (17.9)
II20 (87)2 (66.7)15 (88.2)3 (100)23 (82.1)
III1 (4.3)1 (33.3)0 (0)0 (0)0 (0)0.3240.693
Time from surgery to treatmentDays22.9 (10.9)15 (5.2)25.2 (11.7)18 (2)
Weightkg24.6 (11.7)30.1 (4.6)22.1 (12.1)33.3 (9.1)27.1 (11.3)0.4450.178
Time to initiation of chemotherapyDays43.7 (11.3)35.3 (5.5)46.2 (12.2)38.7 (3.1)20.8 (6.5)00
DoxorubicinDoses4.3 (1.4)4.3 (1.2)4.4 (1.5)4 (1.7)4.1 (1.2)0.6690.628
B. Study protocol timeline
SplenectomyeBATeBATeBATRecheckDoxorubicinRecheck, doxorubicin
-10-013582122-180
Blood UA PE, stagingBlood PK, NA PEBlood PEBlood PK PEBlood NA PEBlood NA PEBlood Staging PE
  • NOTE: Blood: complete blood count, serum biochemical profile, prothrombin time, partial thromboplastin time; doxorubicin: Adriamycin chemotherapy (30 mg/m2) intravenously every 3 weeks.

  • Abbreviations: BCS, body condition score; eBAT, EGF-bispecific angiotoxin; PE, physical examination; PK, pharmacokinetics; UA, urinalysis.

  • aP value for comparison group versus all dogs.

  • bP value for comparison group versus dose level 2.

  • cBCS was missing for 2 control dogs. Four breeds enrolled in the study included 5 Labrador retrievers, 3 mixed breed, 2 English springer spaniels, and 1 each English setter, Brittany Spaniel, Airedale Terrier, Bichon Frise, Newfoundland, Vizsla, Goldendoodle, Cairn Terrier, Papillon, Dachshund, Golden Retriever, Rat Terrier, and German Shepherd Dog.